These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 21670469)
1. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Alizadeh AA; Gentles AJ; Alencar AJ; Liu CL; Kohrt HE; Houot R; Goldstein MJ; Zhao S; Natkunam Y; Advani RH; Gascoyne RD; Briones J; Tibshirani RJ; Myklebust JH; Plevritis SK; Lossos IS; Levy R Blood; 2011 Aug; 118(5):1350-8. PubMed ID: 21670469 [TBL] [Abstract][Full Text] [Related]
2. Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling. Mosquera Orgueira A; Díaz Arias JÁ; Cid López M; Peleteiro Raíndo A; Antelo Rodríguez B; Aliste Santos C; Alonso Vence N; Bendaña López Á; Abuín Blanco A; Bao Pérez L; González Pérez MS; Pérez Encinas MM; Fraga Rodríguez MF; Bello López JL BMC Cancer; 2020 Oct; 20(1):1017. PubMed ID: 33087075 [TBL] [Abstract][Full Text] [Related]
3. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ciavarella S; Vegliante MC; Fabbri M; De Summa S; Melle F; Motta G; De Iuliis V; Opinto G; Enjuanes A; Rega S; Gulino A; Agostinelli C; Scattone A; Tommasi S; Mangia A; Mele F; Simone G; Zito AF; Ingravallo G; Vitolo U; Chiappella A; Tarella C; Gianni AM; Rambaldi A; Zinzani PL; Casadei B; Derenzini E; Loseto G; Pileri A; Tabanelli V; Fiori S; Rivas-Delgado A; López-Guillermo A; Venesio T; Sapino A; Campo E; Tripodo C; Guarini A; Pileri SA Ann Oncol; 2018 Dec; 29(12):2363-2370. PubMed ID: 30307529 [TBL] [Abstract][Full Text] [Related]
4. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma. Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y Front Immunol; 2021; 12():732006. PubMed ID: 34745101 [TBL] [Abstract][Full Text] [Related]
5. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713 [TBL] [Abstract][Full Text] [Related]
6. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797 [TBL] [Abstract][Full Text] [Related]
7. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas. Shams TM J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842 [TBL] [Abstract][Full Text] [Related]
9. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Lossos IS; Jones CD; Warnke R; Natkunam Y; Kaizer H; Zehnder JL; Tibshirani R; Levy R Blood; 2001 Aug; 98(4):945-51. PubMed ID: 11493437 [TBL] [Abstract][Full Text] [Related]
10. A few good genes: simple, biologically motivated signatures for cancer prognosis. Gentles AJ; Alizadeh AA Cell Cycle; 2011 Nov; 10(21):3615-6. PubMed ID: 22037208 [No Abstract] [Full Text] [Related]
11. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757 [TBL] [Abstract][Full Text] [Related]
12. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Natkunam Y; Zhao S; Mason DY; Chen J; Taidi B; Jones M; Hammer AS; Hamilton Dutoit S; Lossos IS; Levy R Blood; 2007 Feb; 109(4):1636-42. PubMed ID: 17038524 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of 'double-hit' and 'double-expression' lymphomas. Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842 [TBL] [Abstract][Full Text] [Related]
14. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Jais JP; Haioun C; Molina TJ; Rickman DS; de Reynies A; Berger F; Gisselbrecht C; Brière J; Reyes F; Gaulard P; Feugier P; Labouyrie E; Tilly H; Bastard C; Coiffier B; Salles G; Leroy K; Leukemia; 2008 Oct; 22(10):1917-24. PubMed ID: 18615101 [TBL] [Abstract][Full Text] [Related]
15. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790 [TBL] [Abstract][Full Text] [Related]
16. Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score. Tekin N; Omidvar N; Morris TP; Conget P; Bruna F; Timar B; Gagyi E; Basak R; Naik O; Auewarakul C; Sritana N; Levy D; Cerci JJ; Bydlowski SP; Pereira J; Dimamay MP; Natividad F; Chung JK; Belder N; Kuzu I; Paez D; Dondi M; Carr R; Ozdag H; Padua RA Oncotarget; 2016 Dec; 7(50):83319-83329. PubMed ID: 27825111 [TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907 [No Abstract] [Full Text] [Related]
18. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G; Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369 [TBL] [Abstract][Full Text] [Related]
19. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma. Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885 [TBL] [Abstract][Full Text] [Related]
20. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma. Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]